ESMO

Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumour (GIST): Long-term update from the phase 3 INVICTUS study.

A phase 1b/2 study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer.

Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT).

Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor. (GIST)

The INVICTUS Trial: Ripretinib As ≥4th-Line Therapy In Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Initial Results of Phase 1 Study of DCC-2618, a Broad-Spectrum KIT and PDGFR⍺ Inhibitor, in Patients (PTS) with Gastrointestinal Stromal Tumor (GIST) by Number of Prior Regimens.

INVICTUS, A Phase 3, INterVentional , Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of Ripretinib as ≥4th Line Therapy In Patients with AdvanCed Gastrointestinal Stromal TUmorS (GIST) Who Have Received Treatment with Prior Anticancer Therapies (NCT03353753).

A phase 1b/2 study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer. 

A phase 1 study of rebastinib and carboplatin in patients with metastatic solid tumors. 

Clinical Benefit with Ripretinib as ≥4th Line Treatment in Patients with Advanced Gastrointestinal Stromal Tumors (GIST): Update from the Phase 3 INVICTUS Study.